Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Immunogenicity of BG505 SOSIP.664 gp140 Vaccine in Adults
NCT05983874Phase 1Enrolling by invitation
- Sponsor
- International AIDS Vaccine Initiative
- Start
- Apr 2024
- Primary completion
- Mar 2025
- Modality
- Recombinant Protein Vaccines, Fc-Fusion Proteins
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of BG505 SOSIP.664 gp140 in human immunodeficiency virus infection (HIV), sponsored by International AIDS Vaccine Initiative. Primary endpoints: Proportion of participants with Grade 2 or greater reactogenicity, Proportion of participants with vaccine-related unsolicited AEs and 3 more. Started Apr 2024; status: enrolling by invitation.
02
Drugs
BG505 SOSIP.664 gp140
03
Conditions
human immunodeficiency virus infection (HIV)
Beyond the preview
Go deeper on NCT05983874.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05983874.